2-(Chloromethyl)-3-phenylquinazolin-4(3H)-ones as potent anticancer agents; cytotoxicity, molecular docking and in silico studies


In order to show antiproliferation and cancerous cell growth inhibition of quinazoline derivatives, a series of 2-(chloromethyl)-3-phenylquinazolin-4(3H)-ones (H1H11) were synthesized. In vitro cytotoxic activities were evaluated against three human cancer cell lines: A549, MCF-7 and SW1116 using colorimetric MTT assay. Comparing their effects together and with cisplatin as a positive control indicated that H3, H5 and H6 exhibited better antitumor activities on A549 cell line with IC50 values less than 10 μM versus 12 μM for cisplatin. In the case of MCF-7 and SW1116 cell lines, almost all compounds displayed better cytotoxic activities than cisplatin. Molecular docking studies were applied on epidermal growth factor receptor (EGFR) as the main target of quinazoline scaffolds in cancer therapy to predict the binding energies, binding modes and orientation of these ligands toward the active site of the receptor. In silico physicochemical parameters and ADMET profiling calculations also were done. All compounds showed lower binding energies than erlotinib, the inhibitor of EGFR. Taken together, our findings showed potential anticancer effect of quinazoline compounds bearing various phenyl ring substitutions.

Graphic abstract

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Scheme 1
Scheme 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. 1.

    M. Saeedi, M. Mohammadi-Khanaposhtani, P. Pourrabia, N. Razzaghi, R. Ghadimi, S. Imanparast, Bioorg. Chem. 83, 161 (2019)

    CAS  Article  Google Scholar 

  2. 2.

    S. Ravez, O. Castillo-Aguilera, P. Depreux, L. Goossens, Expert Opin. Ther. Pat. 25, 789 (2015)

    CAS  Article  Google Scholar 

  3. 3.

    P.C. Sharma, G. Kaur, R. Pahwa, A. Sharma, H. Rajak, Curr. Med. Chem. 18, 4786 (2011)

    CAS  Article  Google Scholar 

  4. 4.

    K. Rakesh, H. Manukumar, D.C. Gowda, Bioorg. Med. Chem. Lett 25, 1072 (2015)

    CAS  Article  Google Scholar 

  5. 5.

    S. Gatadi, T.V. Lakshmi, S. Nanduri, Eur. J. Med. Chem. 170, 157 (2019)

    CAS  Article  Google Scholar 

  6. 6.

    J. Bartroli, E. Turmo, M. Algueró, E. Boncompte, M.L. Vericat, L. Conte, J. Med. Chem. 41, 1869 (1998)

    CAS  Article  Google Scholar 

  7. 7.

    Z. Wang, M. Wang, X. Yao, Y. Li, J. Tan, L. Wang, Eur. J. Med. Chem. 53, 275 (2012)

    CAS  Article  Google Scholar 

  8. 8.

    A. Hameed, M. Al-Rashida, M. Uroos, S.A. Ali, A.M. Ishtiaq, Expert Opin. Ther. Pat. 28, 281 (2018)

    CAS  Article  Google Scholar 

  9. 9.

    Y. Le, Y. Gan, Y. Fu, J. Liu, W. Li, X. Zou, J. Enzyme. Inhib. Med. 35, 555 (2020)

    CAS  Article  Google Scholar 

  10. 10.

    A.-M. Alaa, L.A. Abou-Zeid, K.E.H. ElTahir, R.R. Ayyad, A.-A. Magda, A.S. El-Azab, Euro. J. Med. Chem. 121, 410 (2016)

    Article  Google Scholar 

  11. 11.

    J. Fricker, Lancet. Oncol. 7, 621 (2006)

    Article  Google Scholar 

  12. 12.

    S. Garofalo, R. Rosa, R. Bianco, G, , Tortora. Expert Opin. Ther. Pat. 18, 889 (2008)

    CAS  Article  Google Scholar 

  13. 13.

    G. Marzaro, A. Guiotto, A. Chilin, Expert Opin. Ther. Pat. 22, 223 (2012)

    CAS  Article  Google Scholar 

  14. 14.

    M.N. Noolvi, H.M. Patel, V. Bhardwaj, A. Chauhan, Euro. J. Med. Chem. 46, 2327 (2011)

    CAS  Article  Google Scholar 

  15. 15.

    W. Dohle, F.L. Jourdan, G. Menchon, A.E. Prota, P.A. Foster, P. Mannion, J. Med. Chem. 61, 1031 (2018)

    CAS  Article  Google Scholar 

  16. 16.

    S. El-Sayed, K. Metwally, A.A. El-Shanawani, L.M. Abdel-Aziz, H. Pratsinis, D. Kletsas, Chem. Cent. J. 11, 1 (2017)

    Article  Google Scholar 

  17. 17.

    F.L. Faraj, M. Zahedifard, M. Paydar, C.Y. Looi, N. Abdul Majid, H.M. Ali, Sci. World J. 2014, 1 (2014)

  18. 18.

    N. Rahmannejadi, S. Khabnadideh, I. Yavari, Monatsh. Chem. 149, 2085 (2018)

    CAS  Article  Google Scholar 

  19. 19.

    N. Rahmannejadi, I. Yavari, S. Khabnadideh, J. Heterocycl. Chem. 57, 978 (2020)

    CAS  Article  Google Scholar 

  20. 20.

    N. Rahmannejadi, K. Zomorodian, Z. Faghih, Z. Faghih, S. Khabnadideh, J. Pharm. Res. Int. 20, 1 (2017)

  21. 21.

    Z. Faghih, N. Rahmannejadi, R. Sabet, K. Zomorodian, M. Asad, S. Khabnadideh, Res. Pharm. Sci. 14, 115 (2019)

    Article  Google Scholar 

  22. 22.

    P. Ramesh, D. Srinivasulu, D. Subbarao, K. Hemakumar, D. Rajasekhar, C. Nagaraju, Der Pharm. Lett. 4, 1344 (2012)

    CAS  Google Scholar 

  23. 23.

    H. Patel, A. Shirkhedkar, S. Bari, K. Patil, A. Arambhi, C. Pardeshi, Bull. Fac. Pharm. 56, 83 (2018)

    Google Scholar 

  24. 24.

    P. Selvam, N. Murugesh, M. Chandramohan, C. Pannecouque, E.D. Clercq, Indian J. Pharm. Sci. 72, 806 (2010)

    CAS  Article  Google Scholar 

  25. 25.

    H.-Z. Li, H.-Y. He, Y.-Y. Han, X. Gu, L. He, Q.-R. Qi, Molecules 15, 9473 (2010)

    CAS  Article  Google Scholar 

  26. 26.

    Z. Faghih, A. Neshat, P. Mastrorilli, V. Gallo, Z. Faghih, S. Gilanchi, Inorg. Chim. Acta. 512, 119896 (2020)

    CAS  Article  Google Scholar 

  27. 27.

    M. Fereidoonnezhad, H.R. Shahsavari, S. Abedanzadeh, A. Nezafati, A. Khazali, P. Mastrorilli, M. Babaghasabha, J. Webb, Z. Faghih, Z. Faghih, S. Bahemmat, M. Hassan Beyzavi, New J. Chem. 42, 8681 (2018)

    CAS  Article  Google Scholar 

  28. 28.

    W. Humphrey, A. Dalke, K. Schulten, J. Mol. Graph. 14, 33 (1996)

    CAS  Article  Google Scholar 

  29. 29.

    M. Fereidoonnezhad, S.M.H. Tabaei, A. Sakhteman, H. Seradj, Z. Faghih, Z. Faghih, J. Mol. Struct. 1221, 128689 (2020)

    CAS  Article  Google Scholar 

  30. 30.

    M. Fereidoonnezhad, Z. Faghih, A. Mojaddami, Z. Rezaei, A. Sakhteman, Int. J. Pharm. Res. 16, 981 (2017)

    CAS  Google Scholar 

  31. 31.

    R. Sabet, S. Khabnadideh, D. Fathi, L. Emami, J. Pharm. Res. Int. 22, 1 (2019)

    Article  Google Scholar 

  32. 32.

    L. Emami, L. Zamani, R. Sabet, K. Zomorodian, Z. Rezaei, Z. Faghih, Trends Pharmacol. Sci. 6, 113 (2020)

    CAS  Google Scholar 

  33. 33.

    R.S. Giri, H.M. Thaker, T. Giordano, J. Williams, D. Rogers, K.K. Vasu, Bioorg. Med. Chem. 18, 2796 (2010)

    CAS  Article  Google Scholar 

  34. 34.

    K. Metwally, H. Pratsinis, D. Kletsas, Eur. J. Med. Chem. 133, 340 (2017)

    CAS  Article  Google Scholar 

  35. 35.

    W. Huang, R. Huang, M.S. Attene-Ramos, S. Sakamuru, E.E. Englund, J. Inglese, Bioorg. Med Chem. Lett. 21, 5239 (2011)

    CAS  Article  Google Scholar 

Download references


Financial support from the Shiraz University of Medical Sciences with Grant numbers of 98-01-36-21224 and 99-01-16-23354 is gratefully acknowledged.

Author information



Corresponding authors

Correspondence to Zeinab Faghih or Zahra Faghih.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 1811 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Emami, L., Faghih, Z., Khabnadideh, S. et al. 2-(Chloromethyl)-3-phenylquinazolin-4(3H)-ones as potent anticancer agents; cytotoxicity, molecular docking and in silico studies. J IRAN CHEM SOC (2021). https://doi.org/10.1007/s13738-021-02168-1

Download citation


  • Quinazoline
  • Cytotoxicity
  • EGFR
  • Molecular docking